Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-1237.07%
operating margin TTM
-1273.72%
revenue TTM
2.19 Million
revenue per share TTM
0.25$
valuation ratios | |
|---|---|
| pe ratio | -2.41 |
| peg ratio | -0.76 |
| price to book ratio | 7.35 |
| price to sales ratio | 30.92 |
| enterprise value multiple | -3.29 |
| price fair value | 7.35 |
profitability ratios | |
|---|---|
| gross profit margin | 99.84% |
| operating profit margin | -1273.72% |
| pretax profit margin | -1237.07% |
| net profit margin | -1237.07% |
| return on assets | -86.01% |
| return on equity | -197.75% |
| return on capital employed | -141.14% |
liquidity ratios | |
|---|---|
| current ratio | 2.66 |
| quick ratio | 2.66 |
| cash ratio | 2.08 |
efficiency ratios | |
|---|---|
| days of inventory outstanding | 0.00 |
| operating cycle | 52.31 |
| days of payables outstanding | 265,537.50 |
| cash conversion cycle | -265,485.19 |
| receivables turnover | 6.98 |
| payables turnover | 0.00 |
| inventory turnover | 0.00 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.01 |
| debt equity ratio | 0.04 |
| long term debt to capitalization | 0.00 |
| total debt to capitalization | 0.03 |
| interest coverage | 0.00 |
| cash flow to debt ratio | -66.20 |
cash flow ratios | |
|---|---|
| free cash flow per share | -1.37 |
| cash per share | 1.62 |
| operating cash flow per share | -1.37 |
| free cash flow operating cash flow ratio | 1.00 |
| cash flow coverage ratios | -66.20 |
| short term coverage ratios | 0.00 |
| capital expenditure coverage ratio | 0.00 |
Frequently Asked Questions
When was the last time Lumos Pharma, Inc. (NASDAQ:LUMO) reported earnings?
Lumos Pharma, Inc. (LUMO) published its most recent earnings results on 07-11-2024.
What is Lumos Pharma, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Lumos Pharma, Inc. (NASDAQ:LUMO)'s trailing twelve months ROE is -197.75%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Lumos Pharma, Inc. (LUMO) currently has a ROA of -86.01%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did LUMO's net profit margin stand at?
LUMO reported a profit margin of -1237.07% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is LUMO's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 2.66 in the most recent quarter. The quick ratio stood at 2.66, with a Debt/Eq ratio of 0.04.